Company intelligence / Profile preview

Sérélys Pharma

Monaco, Monaco-Ville, Monacoserelyspharma.com ↗

Ownership: Private
Employees: ~49
Development stage: Commercial

Overview

The company's products, particularly Sérélys Meno for menopause, have been documented in clinical studies with over 1000 patients, showing efficacy in reducing menopausal symptoms. Their Femaxeen® product for urinary incontinence has been shown to reduce involuntary urine leaks by over 45% within 2 months in a randomized, double-blind, placebo-controlled study.

Therapeutic areas: NephrologyEndocrinologyImmunologyCardiovascularNeurologyWomen's Health
Modalities: Natural food supplementsNon-hormonal treatments
Industry: Food & Nutrition

Drug pipeline

5 assets

Serelys MENO

Commercial

Indications: Menopause symptoms

4 more assets in the full pipeline.

Request access →

Partnerships

Partnerships with leading pharmaceutical companies in numerous countries

Beyond the preview

Go deeper on Sérélys Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sérélys Pharma.

Explore the full profile